By Adriano Marchese

AstraZeneca PLC (AZN.LN) said Thursday that it has received marketing authorization from China's national medical products administration for Imfinzi for the treatment of patients with stage III nonsmall-cell lung cancer.

The U.K. pharmaceuticals company said approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III Pacific trial.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

December 12, 2019 02:38 ET (07:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Astrazeneca Charts.